Brensocatib has demonstrated efficacy in reducing neutrophil serine protease activity and symptom burden in non-cystic fibrosis bronchiectasis. GLP-1 inhibitors show potential in managing obstructive ...
Please provide your email address to receive an email when new articles are posted on . Brensocatib given as 25 mg performed better than placebo when assessing rate of pulmonary exacerbations and lung ...
—Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— ...
Highly symptomatic bronchiectasis patients have increased exacerbation risks, regardless of previous exacerbation history or disease severity. Current guidelines do not recommend preventive treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results